AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05368883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise-Two-Legged
Description: The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
Study NCT04999488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPM31510
Description: A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Study NCT06291987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib will be given at assigned dose once daily.
Study NCT06291987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given at assigned dose twice daily.
Study NCT06645314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: 3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
Study NCT06645314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: 3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
Study NCT06492460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug：Cisplatin
Description: Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy
Study NCT05308446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT05308446 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV
Study NCT05308446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT05308446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Encorafenib
Description: Given PO
Study NCT05308446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04999488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
Study NCT04901676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab
Description: Leronlimab 700 mg (first dose) followed by weekly 350 mg
Study NCT04901676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06020131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Mobility Rehabilitation
Description: Thoracic mobility exercises: Thoracic extension on foam roller, Sidelying thoracic rotation, Quadruped thoracic rotation, Squat with extension and rotation ( 10 reps x 3 set - 2 times x wk - 8 wk)
Study NCT06020131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Stability Rehabilitation
Description: Lumbopelvic Stabilization Exercises : Bridge with alternate leg, Single leg bridge, Four point kneeling with arm and leg extension, Side plank on front arm with knee flexed (right, left), Sitting on a Swiss Ball and hip flexion (10 reps x 3 set - 2times/wk - 8 wk)
Study NCT06020131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle Strengthening Home Exercises
Description: Ankle Strengthening exercises with resistive band (dorsiflexion, plantarflexion, inversion, eversion) (10 reps x 3 set - 3 times/wk)
Study NCT04630912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: There is no specific protocol for ACT with dementia, therefore a published ACT protocol, 'Better Living with Illness' (Brassington et al., 2016), will be used flexibly to guide the intervention.
Study NCT04829760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
Study NCT04829760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coarse wheat bran
Description: Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
Study NCT04829760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
Study NCT04783116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanols (3g/day)
Description: Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
Study NCT04783116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
Study NCT06031220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing exercise inform of diaphragmatic and costal breathing
Description: deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
Study NCT05840471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
Study NCT05840471 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose water 5%
Description: This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
Study NCT04387071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
Description: Given IT
Study NCT04387071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLP-encapsulated TLR9 Agonist CMP-001
Description: Given SC and IT
Study NCT05146726 — intervention group
Intervention type: OTHER
Intervention: BARMER anemia treatment
Description: BARMER insured patients are informed about the machine autotransfusion directly by the patient blood management (PBM) service and its intraoperative use is organized. The aim of these measures is to ensure that the intraoperative transfusion trigger does not fall below the intraoperative transfusion trigger by integrating the PBM into standard care and to avoid a perioperative transfusion. In addition, a postoperative treatment recommendation is made for the cause-related anemia treatment, e.g. in order to reduce the risk of a renewed anemia-related perioperative transfusion risk in the event of a possible follow-up operation or other elective operations.
Study NCT05146726 — intervention group
Intervention type: OTHER
Intervention: NON-BARMER anemia treatment
Description: Patients not insured with BARMER also receive early anemia detection, selection according to indication intervention (transfusion probability> 10%) and evaluation for machine autotransfusion through the above-mentioned patient blood management (PBM) restructuring of standard care. In the case of preoperative anemia before an indication intervention and / or an intervention with machine autotransfusion application, the operating clinic will be given a recommendation by the PBM service for the diagnosis and treatment of the preoperative anemia and / or the use of the machine autotransfusion (implementation is the responsibility of the operating clinic)
Study NCT05812807 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT05812807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation
Study NCT05812807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05812807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05812807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05812807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05812807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05812807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05812807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05812807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05250908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTIBIA Therapeutic
Description: INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
Study NCT05250908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTIBIA Non-Therapeutic
Description: INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
Study NCT06300411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRG-514
Description: SRG-514 monotherapy
Study NCT06288438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Techniques
Description: Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
Study NCT06288438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Interventions
Description: Strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise.
Study NCT06288438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene, etc.
Study NCT06288438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Status Updates
Description: Health Status Updates will be completed by a trained assessor. The assessor will ask about adverse events, general health topics, medication changes, and changes in social circumstances.
Study NCT06288438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy Consult
Description: Participants in the control condition will be offered a physical therapy consult at the end of their 24 week study involvement.
Study NCT06634875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isunakinra
Description: Isunakinra is a potent IL1R1 inhibitor
Study NCT05629286 — intervention group
Intervention type: DEVICE
Intervention: McConnell taping
Description: non-stretch rigid McConnell tape will be applied
Study NCT05629286 — intervention group
Intervention type: DEVICE
Intervention: Patella Stabilizer Brace
Description: An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
Study NCT06632080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P
Description: The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
Study NCT06632080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
Study NCT05761366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-PSMA-BCH PET/CT
Description: Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
Study NCT05617326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAA screening by a GP
Description: The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..
Study NCT05617326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AAA screening by a radiologist
Description: General practitioners in the control group will refer their patients to the radiologist for AAA screening.
Study NCT06016842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elafibranor
Description: Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
Study NCT06016842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched 80 mg placebo
Description: Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily
Study NCT06256055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMYM802 Injection
Description: 1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
Study NCT05467410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COG-AM
Description: Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
Study NCT05467410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COG-PM
Description: Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
Study NCT05534867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Description: Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
Study NCT06490887 — intervention group
Intervention type: OTHER
Intervention: Use of patient-derived biological samples
Description: We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
Study NCT06399224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local Plantar vibrator
Description: A vibrating device that applies 80 hz vibration waves applied on the sole of the foot
Study NCT06399224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Otago exercise
Description: Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
Study NCT05424302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation
Description: The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
Study NCT05424302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Vestibular Rehabilitation with Adjunct Auditory Intervention
Description: The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
Study NCT05692947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core body temperature device
Description: This study is to verify the claims of CORE™ body temperature system to estimate core body temperature from skin temperature and heart rate during exercise under varying environmental conditions. Subjects will ingest a temperature sensing pill and be outfitted with skin temperature sensors, a chest strap heart rate monitor, and the CORE and CaleraResearch devices. Athletes will run or cycle in hot/dry and hot/humid conditions for 45 minutes at an absolute workload of 60% VO2 Max/Peak.
Study NCT04643405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387 for Injection
Description: APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
Study NCT04643405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
Study NCT04643405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel 125mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.
Study NCT05505279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE (High Flow Nasal Cannula)
Description: 2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen
Study NCT05268042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderately carbohydrate-restricted diet
Description: For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.
Study NCT05268042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat-restricted diet
Description: The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
Study NCT05586230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Administered orally based on participant's weight
Study NCT05586230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
Study NCT05765799 — intervention group
Intervention type: OTHER
Intervention: Questionary
Description: Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).